Associated Papers
Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy.
Keller-Evans RB et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
Preanalytical Histology Review Improves POLE Mutation Detection in Endometrial Carcinomas.
Huang H et al.
The Journal of Molecular Diagnostics : Jmd, 2026
Pitfalls in MLH1 promoter methylation assessment, including POLEmut/MLH1meth endometrial adenocarcinoma.
Flaus A et al.
Pathology, Research and Practice, 2026
Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications.
Viana-Errasti J et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Comparison between a Luminex-based multiplex kit with a sequence-specific oligonucleotide probe and next-generation sequencing for the detection of POLE oncogenic mutations in endometrial cancer.
Kato MK et al.
Virchows Archiv : an International Journal of Pathology, 2025
Functions, interactions and prognostic role of POLE: a bioinformatics analysis.
Carvajal-Veloza J et al.
Journal of Gynecologic Oncology, 2025
POLE-mutated endometrial cancer: new perspectives on the horizon?
Fanale D et al.
Frontiers in Oncology, 2025
Morphomolecular Correlation and Clinicopathologic Analysis in Endometrial Carcinoma.
Bülbül G et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists, 2024
Human DNA polymerase ε is a source of C>T mutations at CpG dinucleotides.
Tomkova M et al.
Nature Genetics, 2024
Evaluation of the Accuracy of a Polymerase Chain Reaction-Based Assay for Polymerase Tifilon Mutation Detection in Endometrial Carcinoma.
Chen T et al.
Archives of Pathology & Laboratory Medicine, 2024
Morules and β-catenin predict POLE mutation status in endometrial cancer: A pathway to more cost-effective diagnostic procedures.
Fan R et al.
American Journal of Clinical Pathology, 2024
Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
Espinosa I et al.
Gynecologic Oncology, 2024
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
Ambrosini M et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2024
DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
Ostroverkhova D et al.
Cell Reports, 2024
Exploring the basis of heterogeneity of cancer aggressiveness among the mutated POLE variants.
Selves J et al.
Life Science Alliance, 2024
The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive Review.
Yao X et al.
Cancer Management and Research, 2024
The game-changing impact of POLE mutations in oncology-a review from a gynecologic oncology perspective.
Kögl J et al.
Frontiers in Oncology, 2024
Validation of Modaplex POLE mutation assay in endometrial carcinoma.
Dorca E et al.
Virchows Archiv : an International Journal of Pathology, 2023
Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1.
Mur P et al.
Genome Medicine, 2023
In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries.
Das Ghosh D et al.
Gynecologic Oncology Reports, 2023
QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction.
Van den Heerik ASVM et al.
Jco Global Oncology, 2023
A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report.
Cui J et al.
Diagnostic Pathology, 2023
PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon.
Rousseau B et al.
Cancer Discovery, 2022
Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience.
Devereaux KA et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2022
POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX et al.
Clinical and Translational Medicine, 2021
Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade.
Galati MA et al.
Cancer Research, 2020
POLE Mutation Spectra Are Shaped by the Mutant Allele Identity, Its Abundance, and Mismatch Repair Status.
Hodel KP et al.
Molecular Cell, 2020
Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A et al.
The Journal of Pathology, 2020
Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.
León-Castillo A et al.
The Journal of Pathology, 2020
Diversity spectrum analysis identifies mutation-specific effects of cancer driver genes.
Dong X et al.
Communications Biology, 2020
POLE Mutation Characteristics in a Chinese Cohort with Endometrial Carcinoma.
Li Y et al.
Oncotargets and Therapy, 2020
POLE proofreading defects: Contributions to mutagenesis and cancer.
Park VS et al.
Dna Repair, 2019
Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW et al.
Gynecologic Oncology, 2019
Detection of POLE Subtypes in High-Grade Endometrioid Carcinoma by BaseScope-ISH Assay.
Yu S et al.
Frontiers in Oncology, 2019
Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D et al.
The Journal of Pathology, 2018
Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
Haruma T et al.
Plos One, 2018
Comprehensive Analysis of Hypermutation in Human Cancer.
Campbell BB et al.
Cell, 2017